MBK 105
Alternative Names: MBK-105Latest Information Update: 28 Dec 2023
At a glance
- Originator Mablink Bioscience
- Class Alkaloids; Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 29 Jun 2023 MBK 105 is available for licensing as of 29 Jun 2023. https://www.mablink.com/about-us
- 29 Jun 2023 Early research in Solid tumours in France, prior to June 2023 (Parenteral) (Mablink Bioscience pipeline, June 2023)
- 27 Apr 2021 Mablink Bioscience has patent protection for PSARlink™ technology